News

Grenova Announces Katherine Marrs as New CEO to Drive Innovation and Growth

Grenova, an industry leader in sustainable laboratory solutions, has appointed Katherine Marrs as its new Chief Executive Officer (CEO). Marrs succeeds Lane Major, who has served as CEO since 2023 and will continue to support Grenova as a member of the Board of Directors.

Marrs has been instrumental in driving Grenova’s growth strategy as the company’s Chief Commercial Officer for the past 16 months. Her leadership has been pivotal in expanding Grenova’s presence in the European market and enhancing its commitment to sustainability within the Life Sciences industry.

“We are at an exciting juncture, and I am honored to lead Grenova as we drive forward,” said Marrs. “I look forward to building on our team’s accomplishments, enhancing our innovative product portfolio, advancing our automation and integration capabilities, and furthering our commitment to helping laboratories reduce their environmental footprint.”

Lane Major expressed his confidence in Marrs’ ability to lead Grenova into its next chapter. “Katherine has demonstrated remarkable vision and leadership during her time as Chief Commercial Officer. Her deep understanding of our business and commitment to innovation make her the perfect choice to lead Grenova.”

Ted Lundberg, Chairman of the Board of Directors for Grenova and Co-Founder of Peloton Equity, Grenova’s majority owner, said, “Katherine has shown remarkable skill in guiding Grenova’s commercial strategy and building a solid foundation for the company’s future. Her dedication, expertise, and strategic focus have proven invaluable, and we look forward to her continued success as CEO.”

As Grenova continues expanding its solutions, Marrs will leverage her expertise to enhance the company’s position in the market, foster partnerships that align with Grenova’s mission, and drive initiatives that further its dedication to environmental and economic responsibility.

 

Read more here.

Recent News

09/30/2026

Activation Capital Recognizes President Michael Rao’s 17 Years of Leadership as Authority Board Chair, Names Paul Nolde as New Chair

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced the election of Paul Nolde as chair of the Authority Board, succeeding Virginia Commonwealth University President Michael Rao, Ph.D., who has served as chair since 2009. Rao will remain an active member of the board, continuing his longstanding support of Activation …

09/22/2026

ATCC to Lead Lifecycle Management of Military Medical Countermeasures Under 10-Year Department of War Contract

ATCC has been awarded a 10-year Department of War (DOW) contract to coordinate lifecycle management of medical countermeasures (MCMs) developed to protect U.S. military personnel from chemical and biological threats. Under this contract, ATCC supports the mission of the Rapid Access to Products in Development (RAPID) program to enable MCM preparedness against chemical and biological …

09/22/2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. …